MedPacto, Inc. (KOSDAQ:235980)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,290.00
-105.00 (-3.09%)
Apr 24, 2025, 3:30 PM KST
-66.80%
Market Cap 112.77B
Revenue (ttm) n/a
Net Income (ttm) -20.14B
Shares Out 34.28M
EPS (ttm) -598.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 112,833
Average Volume 122,117
Open 3,395.00
Previous Close 3,395.00
Day's Range 3,150.00 - 3,455.00
52-Week Range 2,750.00 - 10,070.00
Beta 1.12
RSI 53.77
Earnings Date May 9, 2025

About MedPacto

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Seong-Jin Kim
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 235980
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.